Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AxoGen Inc    AXGN

AXOGEN INC

(AXGN)
  Report  
Delayed Quote. Delayed Nasdaq - 06/21 04:00:00 pm
19.61 USD   -0.81%
05/23AXOGEN : to Participate at Upcoming Investor Conferences
AQ
05/08AXOGEN : 1Q Earnings Snapshot
AQ
05/08AXOGEN : Reports 2019 First Quarter Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Law Offices of Howard G. Smith : Announces the Filing of a Securities Class Action on Behalf of AxoGen, Inc. Investors (AXGN)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 07:54pm EDT

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that: a) purchased or otherwise acquired AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities pursuant and/or traceable to the Company’s false and/or misleading registration statement and prospectus (collectively, the “November 2017 Registration Statement”) issued in connection with the Company’s November 2017 secondary public offering (“November SPO”); and/or b) purchased or otherwise acquired AxoGen securities pursuant and/or traceable to the Company’s false and/or misleading registration statement and prospectus (collectively, the “May 2018 Registration Statement”) issued in connection with the Company’s May 2018 secondary public offering (“May SPO”); and/or c) purchased or otherwise acquired AxoGen securities between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”).

On December 18, 2018, Seligman Investments issued a report stating, among other things, that former employees alleged that the Company engaged in channel stuffing and backdating of revenue, that the number of active accounts may be overstated by a factor of ten, and that aggressive annual price increases had driven the Company’s revenue growth.

On this news, the Company’s share price fell $6.17 per share, or nearly 22%, to close at $21.36 per share on December 18, 2018, on unusually high trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company’s pricing alienated customers and threatened the Company’s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company’s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company’s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

If you purchased shares of AxoGen, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AXOGEN INC
05/23AXOGEN : to Participate at Upcoming Investor Conferences
AQ
05/08AXOGEN : 1Q Earnings Snapshot
AQ
05/08AXOGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
05/08AXOGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
05/08AXOGEN : Reports 2019 First Quarter Financial Results
AQ
05/02AXOGEN, INC. : Change in Directors or Principal Officers, Amendments to Articles..
AQ
05/02Axogen, Inc. Appoints New Members to Board of Directors
GL
04/24AXOGEN : shares slip on expanded Avance nerve graft study
AQ
04/23AXOGEN : Announces Completion of Planned Interim Analysis and One-Time Enrollmen..
AQ
04/22AXOGEN, INC. : Results of Operations and Financial Condition, Other Events, Fina..
AQ
More news
Financials ($)
Sales 2019 112 M
EBIT 2019 -21,5 M
Net income 2019 -29,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 6,86x
Capi. / Sales 2020 5,22x
Capitalization 768 M
Chart AXOGEN INC
Duration : Period :
AxoGen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXOGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 33,8 $
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Karen L. Zaderej Chairman, President & Chief Executive Officer
Mike Donovan Vice President-Operations
Peter J. Mariani Chief Financial Officer
Ivica Ducic Medical Director-Clinical & Translational Sciences
Angelo G. Scopelianos Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AXOGEN INC-4.01%826
THERMO FISHER SCIENTIFIC31.58%106 107
DANAHER CORPORATION39.38%94 446
BOSTON SCIENTIFIC CORPORATION17.97%53 248
INTUITIVE SURGICAL10.04%52 907
ILLUMINA20.55%44 647